Holen Sie sich die Stockscreener-App
3.915
5.24%
0.195
Handel nachbörslich:
3.96
0.045
+1.15%
Schlusskurs vom Vortag:
$3.72
Offen:
$3.75
24-Stunden-Volumen:
923.78K
Relative Volume:
1.06
Marktkapitalisierung:
$123.01M
Einnahmen:
$19.09M
Nettoeinkommen (Verlust:
$-82.13M
KGV:
-1.3969
EPS:
-2.8026
Netto-Cashflow:
$-70.00M
1W Leistung:
-3.81%
1M Leistung:
-16.17%
6M Leistung:
-56.84%
1J Leistung:
-90.22%
1-Tages-Spanne:
$3.66
$4.00
1-Wochen-Bereich:
$3.595
$4.175
52-Wochen-Spanne:
$3.595
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
3.915 | 123.01M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
LENZ Therapeutics: Below Cash For A Reason (NASDAQ:LENZ) - Seeking Alpha
Presbyopia Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | AbbVie, Orasis Pharma, Eyenovia, Glaukos Corp., Ocuphire Pharma, Novartis - Barchart.com
BMEA Stock Price and Chart — NASDAQ:BMEA - TradingView
LENZ Therapeutics, Inc. (LENZ): Analyzing The Potential 481% Upside For Investors - directorstalkinterviews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc.LENZ - PR Newswire
LENZ Therapeutics (LENZ): Revenue and EPS Gains on VIZZ Launch Traction, but Operating Losses Signal a Long Road to Profitability - AlphaStreet
LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages LENZ Therapeutics, Inc. (LENZ) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating LENZ Therapeu - The National Law Review
A 5.7% stake in LENZ Therapeutics (LENZ) has been disclosed—but by whom? - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against LENZ Therapeutics, Inc. (LENZ) And Encourages Shareholders to Reach Out - ACCESS Newswire
LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz - The National Law Review
LENZ Therapeutics: Still Speculative But Priced For Disasters (NASDAQ:LENZ) - Seeking Alpha
Lenz Therapeutics faces securities fraud probe after weak product sales and stock plunge. - pluang.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against LENZ Therapeutics, Inc. (LENZ) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against LENZ Therapeutics, Inc. (LENZ) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against LENZ Therapeutics, Inc. (LENZ) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - natlawreview.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against LENZ Therapeutics, Inc. (LENZ) And Encourages Stockholders to Reach Out - ACCESS Newswire
Blue Owl Capital Holdings LP Invests $4.30 Million in LENZ Therapeutics, Inc. $LENZ - MarketBeat
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research - MarketBeat
LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts - Yahoo Finance
LENZ Therapeutics Inc (NASDAQ: LENZ) Share Price, LENZ Stock News, LENZ Share Price & Updates - Kalkine
Q3 EPS Estimate for LENZ Therapeutics Increased by Analyst - MarketBeat
Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83 - simplywall.st
Citi Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ) - Seeking Alpha
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $7 to $38 - Moomoo
BofA Securities Downgrades LENZ Therapeutics(LENZ.US) to Hold Rating, Cuts Target Price to $7 - Moomoo
BofA downgrades Lenz Therapeutics stock rating on slow launch By Investing.com - Investing.com Australia
BofA downgrades Lenz Therapeutics stock rating on slow launch - Investing.com
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - Moomoo
Why is LENZ Therapeutics stock rallying today? - Investing.com
Why is LENZ Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Hold Rating, Cuts Target Price to $7 - Moomoo
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38 - Moomoo
LENZ Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $29.86, Implies 473% Upside - TradingView
LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ... By GuruFocus - Investing.com Canada
Lenz Therapeutics Posts Q2 Revenue Fueled by VIZZ Sales and License Agreements - VisionMonday.com
LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: LENZ Therapeutics tops Q2 2026 forecasts as sales jump - Investing.com Nigeria
LENZ Therapeutics Q2 Earnings Call Highlights - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Issues Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
LENZ Therapeutics Q2 Results: Sales surge 131% vs estimates - scanx.trade
LENZ Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
LENZ: July prescriptions surged 45%+ after telehealth and TV launches, with strong patient persistence - TradingView
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):